Agentix Corp
Agentix Corp., a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States. It develops AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, … Read more
Agentix Corp (AGTX) - Total Assets
Latest total assets as of December 2025: $6.40K USD
Based on the latest financial reports, Agentix Corp (AGTX) holds total assets worth $6.40K USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Agentix Corp - Total Assets Trend (2013–2025)
This chart illustrates how Agentix Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Agentix Corp - Asset Composition Analysis
Current Asset Composition (March 2025)
Agentix Corp's total assets of $6.40K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 4.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Agentix Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Agentix Corp's current assets represent 100.0% of total assets in 2025, unchanged from 100.0% in 2013.
- Cash Position: Cash and equivalents constituted 4.5% of total assets in 2025, down from 100.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Agentix Corp Competitors by Total Assets
Key competitors of Agentix Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Agentix Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Agentix Corp generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Agentix Corp is currently not profitable relative to its asset base.
Agentix Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.00 | 0.05 | 0.18 |
| Quick Ratio | 0.00 | 0.05 | 0.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-3.50 Million | $ -2.92 Million | $ -239.07K |
Agentix Corp - Advanced Valuation Insights
This section examines the relationship between Agentix Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3587.45 |
| Latest Market Cap to Assets Ratio | 15.61 |
| Asset Growth Rate (YoY) | -5.7% |
| Total Assets | $100.27K |
| Market Capitalization | $1.57 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Agentix Corp's assets at a significant premium ( 15.61x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Agentix Corp's assets decreased by 5.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Agentix Corp (2013–2025)
The table below shows the annual total assets of Agentix Corp from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $100.27K | -5.73% |
| 2024-03-31 | $106.37K | -59.31% |
| 2023-03-31 | $261.39K | -10.71% |
| 2022-03-31 | $292.75K | +314684.95% |
| 2021-03-31 | $93.00 | 0.00% |
| 2020-03-31 | $93.00 | -95.89% |
| 2019-03-31 | $2.27K | -68.06% |
| 2018-03-31 | $7.09K | -35.62% |
| 2017-03-31 | $11.02K | -37.13% |
| 2016-03-31 | $17.52K | -87.44% |
| 2014-03-31 | $139.53K | +74.41% |
| 2013-03-31 | $80.00K | -- |